Literature DB >> 15065143

Comparison of combination therapy of adenosine and nitroprusside with adenosine alone in the treatment of angiographic no-reflow phenomenon.

Cem Barcin1, Ali E Denktas, Ryan J Lennon, LaVon Hammes, Stuart T Higano, David R Holmes, Kirk N Garratt, Amir Lerman.   

Abstract

We sought to compare the combination therapy of adenosine and nitroprusside in no-reflow phenomenon during percutaneous coronary intervention. Improvement in coronary flow from no-reflow to postdrug state was evaluated. Patients who received adenosine (n = 21) were compared to ones who received the combination of adenosine and nitroprusside (n = 20) for treatment. Improvement of TIMI flow grades was higher in the group that received combined therapy (1.5 +/- 1.0 vs. 0.8 +/- 0.6; P < 0.05). Combination therapy of adenosine and nitroprusside is safe and provides better improvement in coronary flow compared to intracoronary adenosine alone in case of impaired flow during coronary interventions. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15065143     DOI: 10.1002/ccd.20010

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  9 in total

Review 1.  Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy.

Authors:  Aslan T Turer; Joseph A Hill
Journal:  Am J Cardiol       Date:  2010-08-01       Impact factor: 2.778

Review 2.  Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction.

Authors:  Vijayalakshmi Kunadian; Cafer Zorkun; Scott P Williams; Leah H Biller; Alexandra M Palmer; Katherine J Ogando; Michelle E Lew; Navin Nethala; William J Gibson; Susan J Marble; Jacqueline L Buros; C Michael Gibson
Journal:  J Thromb Thrombolysis       Date:  2008-09-26       Impact factor: 2.300

3.  Transient no reflow following primary percutaneous coronary intervention.

Authors:  Hiroyuki Jinnouchi; Kenichi Sakakura; Hiroshi Wada; Kenshiro Arao; Norifumi Kubo; Yoshitaka Sugawara; Hiroshi Funayama; Shin-ichi Momomura; Junya Ako
Journal:  Heart Vessels       Date:  2013-06-27       Impact factor: 2.037

4.  Efficacy of Shexiang Tongxin Dropping Pills in a Swine Model of Coronary Slow Flow.

Authors:  Yupeng Bai; Mingjing Zhang; Sheng Peng; Yuting Wang; Ye Gu; Qianqian Fang; Liqun Hu
Journal:  Front Physiol       Date:  2022-06-14       Impact factor: 4.755

5.  Distal administration of very high doses of intracoronary adenosine for the treatment of resistant no-reflow.

Authors:  Mohammad-Reza Movahed; Gurpreet Baweja
Journal:  Exp Clin Cardiol       Date:  2008

6.  Non-pharmaco, non-invasive management of coronary no-reflow phenomenon.

Authors:  Santosh Kumar Sinha; Mukesh Jitendra Jha; Puneet Aggarwal; Umeshwar Pandey; Awadesh Kumar Sharma; Mahmodullah Razi; Dibbendhu Khanra; Ramesh Thakur; Vinay Krishna
Journal:  Arch Med Sci Atheroscler Dis       Date:  2020-12-29

Review 7.  Treating and preventing no reflow in the cardiac catheterization laboratory.

Authors:  Ryan Berg; Cyrus Buhari
Journal:  Curr Cardiol Rev       Date:  2012-08

8.  Intracoronary fixed dose of nitroprusside via thrombus aspiration catheter for the prevention of the no-reflow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction.

Authors:  Yu-Jun Zhao; Xiang-Hua Fu; Xiao-Xiao Ma; Dong-Ying Wang; Qiu-Li Dong; Yan-Bo Wang; Wei Li; Kun Xing; Xin-Shun Gu; Yun-Fa Jiang
Journal:  Exp Ther Med       Date:  2013-06-04       Impact factor: 2.447

9.  A Novel Biological Strategy for Myocardial Protection by Intracoronary Delivery of Mitochondria: Safety and Efficacy.

Authors:  Borami Shin; Mossab Y Saeed; Jesse J Esch; Alvise Guariento; David Blitzer; Kamila Moskowitzova; Giovanna Ramirez-Barbieri; Arzoo Orfany; Jerusha K Thedsanamoorthy; Douglas B Cowan; James A Inkster; Erin R Snay; Steven J Staffa; Alan B Packard; David Zurakowski; Pedro J Del Nido; James D McCully
Journal:  JACC Basic Transl Sci       Date:  2019-12-23
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.